One plan - full access

No subscription, no auto-renewal, no hidden terms.
Pay once and use it for 30 days.

PRO plan No auto-renewal
$18

30 days of full access
One-time payment

🌐 US & Global Companies
Get access for 30 days →
♧ Secure payment · Instant access

What is included

  • ✓Full access to detailed company analysis
  • ✓Fundamental screener
  • ✓Advanced stock screener filters
  • ✓5 ratings. Separate lists for US & Global Companies and MOEX
  • ✓Company data export in XLSX and CSV
  • ✓MarketCap’s overall ranking of top companies
  • ✓Analytics updates after each new financial report
⚠ The service is not an investment advisor. Financial statement data from public companies is available to everyone - MarketCap structures and analyzes it.
Eyenovia logo
Eyenovia EYEN
report update icon

Quarterly report 2026-Q1
added 05-15-2026

Eyenovia Balance Sheet 2025-2011 | EYEN

Brief overview of Eyenovia's financial position

Balance sheet changes are traced across five available annual reports between 2020 and 2025.

Assets added +52.7%, reaching $51.8 million from $33.9 million five periods earlier; annual growth near 8.8% remained solid.

Liability growth of -42.5% trailed asset growth of +52.7%. The funding structure became more resilient.

Equity accounts for 79.3% of assets. Against the initial 45.1%, the capital position looks resilient.

Negative net debt of -$5.7 million means cash holdings are larger than debt obligations.

Cash accounts for 12.4% of assets versus 83.7% initially. The change indicates the degree of financial flexibility.

Retained earnings remain negative at -$240.6 million. This may reflect past losses or substantial shareholder distributions, so earnings and buybacks provide important context.

Balance sheet takeaway

Eyenovia has a solid balance sheet cushion. Capital and liquidity support development without excessive reliance on debt.

Annual Balance Sheet Eyenovia

2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Net Debt

-5.72 M -829 K -13.1 M -21.5 M - -27.9 M -14.1 M -19.7 M -5.25 M -3.39 M -2.49 M - - - -

Long Term Debt

207 K 718 K 1.29 M 908 K - 366 K - - - - - - - - -

Long Term Debt Current

512 K 575 K 501 K 485 K - - - - - - - - - - -

Total Non Current Liabilities

- - - - - 404 K 45.4 K 41.6 K - - - - - - -

Total Current Liabilities

2.7 M 16 M 9.53 M 4.51 M 11.2 M 18.2 M 2.91 M 3.1 M 553 K - - - - - -

Total Liabilities

10.7 M 16.8 M 19.8 M 13.8 M 11.2 M 18.6 M 2.96 M 3.14 M 553 K 424 K 420 K - - - -

Retained Earnings

-241 M -195 M -145 M -118 M -90.2 M -77.4 M -57.7 M -36.5 M -19.3 M -14.1 M -10.6 M - - - -

Total Assets

51.8 M 3.67 M 28.8 M 31 M 31.7 M 33.9 M 14.7 M 20 M 5.64 M 3.43 M 2.82 M - - - -

Cash and Cash Equivalents

6.44 M 2.12 M 14.8 M 22.9 M 19.5 M 28.4 M 14.2 M 19.7 M 5.25 M 3.39 M - - - - -

Book Value

41.1 M -13.1 M 9 M 17.2 M 20.5 M 15.3 M 11.7 M 16.9 M 5.09 M 3.01 M 2.4 M - - - -

Total Shareholders Equity

41.1 M -13.1 M 9 M 17.2 M 20.5 M 15.3 M 11.7 M 16.9 M 5.09 M 3.01 M - - - - -

All numbers in USD currency

Quarterly Balance Sheet Eyenovia

2026-Q1 2025-Q3 2025-Q2 2025-Q1 2024-Q4 2024-Q3 2024-Q2 2024-Q1 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Long Term Debt

132 K 342 K 473 K 598 K 718 K 836 K 984 K 1.14 M 1.29 M 1.44 M 1.58 M 1.13 M 908 K - - - - - 7.5 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Total Liabilities

11.6 M 12 M 18.3 M 15.7 M 16.8 M 19.1 M 21.4 M 24.4 M 19.8 M 19.1 M 18.8 M 13.5 M 13.8 M 11.1 M 12 M 10.4 M 11.2 M 20.7 M 21.6 M 16.7 M 18.6 M 18.6 M 18.6 M 18.6 M 2.96 M 2.96 M 2.96 M 2.96 M 3.14 M 3.14 M 3.14 M 3.14 M 553 K 553 K - - - - - - - - - - - - - - - - - - - - - - - - - -

Deferred Revenue

- - - - - - - - - - - - - - - - - 10 M 10 M 12 M 14 M 14 M 14 M 14 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Retained Earnings

-232 M -201 M -207 M -199 M -195 M -175 M -167 M -156 M -145 M -138 M -130 M -124 M -118 M -112 M -105 M -97.6 M -90.2 M -93.2 M -87.6 M -82.8 M -77.4 M -77.4 M -77.4 M -77.4 M -57.7 M -57.7 M -57.7 M -57.7 M -36.5 M -36.5 M -36.5 M -36.5 M -19.3 M -19.3 M -19.3 M -19.3 M -14.1 M - - - - - - - - - - - - - - - - - - - - - - -

Total Assets

70.1 M 82.8 M 55.7 M 5.98 M 3.67 M 22.8 M 19 M 26.2 M 28.8 M 34.9 M 29.3 M 29.3 M 31 M 31.4 M 35.6 M 40.2 M 31.7 M 25 M 30.6 M 28.9 M 33.9 M 33.9 M 33.9 M 33.9 M 14.7 M 14.7 M 14.7 M 14.7 M 20 M 20 M 20 M 20 M 5.64 M 5.64 M 5.64 M 5.64 M 3.43 M - - - - - - - - - - - - - - - - - - - - - - -

Cash and Cash Equivalents

7.38 M 8.22 M 7.53 M 3.93 M 2.12 M 7.19 M 2.3 M 7.98 M 14.8 M 20.7 M 17.5 M 18.5 M 22.9 M 17.4 M 21.5 M 26.7 M 19.5 M 13.5 M 27.2 M 24.9 M 28.4 M 28.4 M 28.4 M 28.4 M 14.2 M 14.2 M 14.2 M 14.2 M 19.7 M 19.7 M 19.7 M 19.7 M 5.25 M 5.25 M 5.25 M 5.25 M 3.39 M - - - 2.49 M - - - - - - - - - - - - - - - - - - -

Book Value

58.5 M 70.8 M 37.4 M -9.71 M -13.1 M 3.72 M -2.37 M 1.82 M 9 M 15.8 M 10.5 M 15.8 M 17.2 M 20.3 M 23.6 M 29.8 M 20.5 M 4.25 M 8.99 M 12.1 M 15.3 M 15.3 M 15.3 M 15.3 M 11.7 M 11.7 M 11.7 M 11.7 M 16.9 M 16.9 M 16.9 M 16.9 M 5.09 M 5.09 M 5.64 M 5.64 M 3.43 M - - - - - - - - - - - - - - - - - - - - - - -

Total Shareholders Equity

58.5 M 70.8 M 37.4 M -9.71 M -13.1 M 3.72 M -2.37 M 1.82 M 9 M 15.8 M 10.5 M 15.8 M 17.2 M 20.3 M 23.6 M 29.8 M 20.5 M 4.25 M 8.99 M 12.1 M 15.3 M 15.3 M 15.3 M 15.3 M 11.7 M 11.7 M 11.7 M 11.7 M 16.9 M 16.9 M 16.9 M 16.9 M 5.09 M 5.09 M 5.09 M 5.09 M 3.01 M - - - 2.4 M - - - - - - - - - - - - - - - - - - -

All numbers in USD currency

Balance Sheet is a fundamental financial report of Eyenovia, providing a complete picture of the company’s financial position at a specific point in time. Unlike the income statement, which records the results of operations over a certain period, the balance sheet shows what assets the company owns, what liabilities it has to creditors, and what equity is available to the owners.

For an investor, the balance sheet is important because it allows assessing the company’s financial stability, understanding how much debt it carries, and how dependent it is on borrowed financing. It helps calculate key liquidity and leverage ratios. When analyzing, attention should be paid to the debt-to-equity ratio (Debt/Equity), the amount of cash on the balance sheet, and the ratio of current liabilities to liquid assets.

Features of balance sheet analysis
  • Vertical and horizontal analysis
    Vertical analysis shows the structure of the balance sheet as a percentage of total assets or liabilities, while horizontal analysis shows the dynamics of changes over multiple periods.
  • Asset quality
    It is important to evaluate not only the amount of assets but also their liquidity and realizability.
  • Accounting for off-balance sheet liabilities
    Some liabilities may not be directly reflected in the balance sheet, which requires additional attention.

Balance sheet of other industry stocks – Biotechnology

Issuer Price % 24h Market Cap Country
KalVista Pharmaceuticals KalVista Pharmaceuticals
KALV
- - $ 1.45 B britainBritain
KemPharm KemPharm
KMPH
- -0.34 % $ 200 M usaUSA
Kezar Life Sciences Kezar Life Sciences
KZR
- - $ 53.3 M usaUSA
Lixte Biotechnology Holdings Lixte Biotechnology Holdings
LIXT
- - $ 63.4 M usaUSA
Magenta Therapeutics Magenta Therapeutics
MGTA
- -7.74 % $ 41.6 M usaUSA
NovaBay Pharmaceuticals NovaBay Pharmaceuticals
NBY
- - $ 11.3 M usaUSA
NeuroBo Pharmaceuticals NeuroBo Pharmaceuticals
NRBO
- 0.43 % $ 12 M usaUSA
OncoCyte Corporation OncoCyte Corporation
OCX
- 17.22 % $ 355 K usaUSA
Onconova Therapeutics Onconova Therapeutics
ONTX
- -0.47 % $ 21 M usaUSA
Opthea Limited Opthea Limited
OPT
- - $ 1.2 B australiaAustralia
BiomX BiomX
PHGE
$ 1.85 14.2 % $ 3.02 M israelIsrael
Pieris Pharmaceuticals Pieris Pharmaceuticals
PIRS
- -15.58 % $ 1.22 B germanyGermany
Plus Therapeutics Plus Therapeutics
PSTV
- - $ 301 M usaUSA
Pluristem Therapeutics Pluristem Therapeutics
PSTI
- -1.9 % $ 33.3 M israelIsrael
Qualigen Therapeutics Qualigen Therapeutics
QLGN
- 5.59 % $ 1.16 M usaUSA
Qilian International Holding Group Limited Qilian International Holding Group Limited
QLI
- -6.08 % $ 184 M chinaChina
Cassava Sciences Cassava Sciences
SAVA
- - $ 110 M usaUSA
Selecta Biosciences Selecta Biosciences
SELB
- -8.69 % $ 126 M usaUSA
Sangamo Therapeutics Sangamo Therapeutics
SGMO
- - $ 50.4 M usaUSA
Salarius Pharmaceuticals Salarius Pharmaceuticals
SLRX
- - $ 2.64 M usaUSA
Sensei Biotherapeutics Sensei Biotherapeutics
SNSE
- - $ 17.5 M usaUSA
Sonnet BioTherapeutics Holdings Sonnet BioTherapeutics Holdings
SONN
- - $ 826 K usaUSA
Synthetic Biologics Synthetic Biologics
SYN
- 1.32 % $ 16.2 M usaUSA
Synlogic Synlogic
SYBX
- - $ 7.07 M usaUSA
Virios Therapeutics, LLC Virios Therapeutics, LLC
VIRI
- 2710.01 % $ 72.9 M usaUSA
Vallon Pharmaceuticals Vallon Pharmaceuticals
VLON
- -6.47 % $ 5.76 M usaUSA
Vaxart Vaxart
VXRT
- -25.06 % $ 46.3 M usaUSA
XOMA Corporation XOMA Corporation
XOMA
- - $ 485 M usaUSA
Repare Therapeutics Repare Therapeutics
RPTX
- - $ 112 M canadaCanada
Sesen Bio Sesen Bio
SESN
- 7.29 % $ 127 M usaUSA
Windtree Therapeutics Windtree Therapeutics
WINT
- - $ 26.8 M usaUSA
Trean Insurance Group Trean Insurance Group
TIG
- - $ 316 M usaUSA
SQZ Biotechnologies Company SQZ Biotechnologies Company
SQZ
- 57.95 % $ 12.8 M usaUSA
MEI Pharma MEI Pharma
MEIP
- 10.43 % $ 20.5 M usaUSA
Palatin Technologies Palatin Technologies
PTN
- - $ 13 M usaUSA
Институт стволовых клеток человека Институт стволовых клеток человека
ISKJ
- - - russiaRussia
ММЦБ ММЦБ
GEMA
- - - russiaRussia
Lyra Therapeutics Lyra Therapeutics
LYRA
- - $ 24.9 M usaUSA
Завод ДИОД Завод ДИОД
DIOD
- - - russiaRussia
Фармсинтез Фармсинтез
LIFE
- - - russiaRussia
ОЗОН Фармацевтика ОЗОН Фармацевтика
OZPH
- - - russiaRussia
Промомед Промомед
PRMD
- - - russiaRussia
Brickell Biotech Brickell Biotech
BBI
- -5.38 % $ 6.06 M usaUSA
Applied Therapeutics Applied Therapeutics
APLT
- - $ 8.42 M usaUSA
ESSA Pharma ESSA Pharma
EPIX
- - $ 8.86 M canadaCanada
Generation Bio Co. Generation Bio Co.
GBIO
- - $ 344 M usaUSA
Clearside Biomedical Clearside Biomedical
CLSD
- - $ 25.3 M usaUSA
Merus N.V. Merus N.V.
MRUS
- - $ 5.78 B niderlandNiderland
RAPT Therapeutics RAPT Therapeutics
RAPT
- - $ 2.36 B usaUSA
Exicure Exicure
XCUR
$ 1.12 0.88 % $ 7.05 M usaUSA